Explore selected peptide research and its documented uncertainties.
Product-specific clinical evidence / GLP-1 receptor
Detailed evidence profile · Compound / preparation
Multiple phase 3 programmes
Large indication-specific randomized trials
Ozempic and Wegovy: distinct indications
GI effects plus important product warnings
Product-specific clinical evidence / GIP / GLP-1 receptors
Detailed evidence profile · Compound / preparation
Multiple phase 3 programmes
Large indication-specific randomized trials
Mounjaro: defined Australian indications
GI effects plus important product warnings
Preclinical + small human reports / Mechanism unresolved
Detailed evidence profile · Compound / preparation
Preclinical work and limited human reports
Small uncontrolled human reports
TGA names BPC-157 products as unapproved
Sparse human safety data
Limited topical human evidence / Copper-binding tripeptide
Detailed evidence profile · Compound / preparation
Small topical studies; preclinical matrix work
One small randomized post-laser study
TGA names GHK-Cu therapeutic products as unapproved
Topical data cannot establish systemic safety
Formulation-specific clinical research / G-actin binding
Detailed evidence profile · Compound / preparation
Ophthalmic phase 3 trials exist
SEER-1: 18 people with neurotrophic keratopathy
Australian government page states no TGA approval
No established safety profile for general systemic use
Human hormone-biomarker research / GHRH receptor
Detailed evidence profile · Compound / preparation
Early human pharmacology; terminated phase 2 registry
Short trials increased GH and IGF-I
TGA names CJC-1295 products as unapproved
Limited trials do not establish long-term safety
Human phase 2 ileus research / Ghrelin receptor
Detailed evidence profile · Compound / preparation
Completed phase 2 postoperative trial
No significant efficacy difference in the selected trial
No Australian approved product established in this review
IV trial events and route-specific evidence gaps
Human indication-specific trials / Immune modulation (research)
Detailed evidence profile · Compound / preparation
Completed phase 3 sepsis trial
Corrected TESTS trial was negative for mortality
No current Australian approved product established
Safety findings are from people with sepsis
Catalogue sources checked; clinical review pending / GLP-1 receptor
Catalogue overview · Compound / preparation
Product-level clinical development established
Weight-management trial checked
Defined adult weight-management products
GI effects and product-specific precautions
Catalogue sources checked; clinical review pending / GLP-1 receptor
Catalogue overview · Compound / preparation
Randomized diabetes evidence
EXSCEL did not show CV superiority
Historical AU decision; dated U.S. label
GI, renal and immune-related risks
Catalogue sources checked; clinical review pending / GLP-1 receptor
Catalogue overview · Compound / preparation
Product-specific human evidence
REWIND primary endpoint favoured dulaglutide
Trulicity: adult type 2 diabetes
GI effects plus important precautions
Catalogue sources checked; clinical review pending / GLP-1 receptor
Catalogue overview · Compound / preparation
Diabetes and cardiovascular evidence
ELIXA showed noninferiority, not superiority
Lyxumia EU authorisation withdrawn
GI effects and clinical precautions
Published snapshots, not live totals. Sources use different inclusion criteria; figures are not additive and do not establish Australian approval.
2022 review snapshot · worldwide · not a count of this demo collection or Australia
Wang et al., Therapeutic peptides: current applications and future directions, Signal Transduction and Targeted Therapy 7, 48. Published 14 February 2022.
Read published source (opens in a new tab)2022 review snapshot · peptides, not registered trials or a 2026 pipeline estimate
Wang et al., Therapeutic peptides: current applications and future directions, Signal Transduction and Targeted Therapy 7, 48. Published 14 February 2022.
Read published source (opens in a new tab)2026 study · CAS dataset, 2020–Aug 2025 · chemical structures, not drugs, candidates, patients or trials
Thite et al., Journal of Medicinal Chemistry 2026;69(15):17770–17799. Published 13 August 2026. Therapeutic, pharmacological and pharmacokinetic indexing analysed with RDKit.
Read published source (opens in a new tab)Four independent questions, not steps toward a safety or effectiveness verdict. A reviewed source would not answer all four on its own.
Define the compound, pathway and question before reading claims.
Read original methods, populations, outcomes and limitations.
Check current official records separately from the studies.
Examine risk reporting and uncertainties independently.
Broad region names only · not precise injection sites or a validated product guide.
Clinical review pending · Prototype
Illustrative areas used for some prescribed subcutaneous medicines. Suitable areas depend on the exact medicine and device; follow its official leaflet and your clinician’s guidance. This diagram does not establish a route or suitable area for unapproved research peptides.
No injection technique or site selection is provided here. This module is separate from research-peptide profiles and does not establish approval or suitability for self-administration.
General anatomy sources · checked 4 October 2026
MedlinePlus / U.S. National Library of Medicine · reviewed 19 October 2025 ↗Broad abdomen, outer upper thigh and side/back upper-arm anatomy for certain medicines; not every peptide.
Wirral Community Health and Care NHS Foundation Trust · reviewed 14 January 2026 ↗Follow the prescribed medicine’s manufacturer leaflet and professional guidance.
For a general example of medicine-specific training, read the Great Ormond Street Hospital subcutaneous-injection resource (opens in a new tab). It is pediatric guidance, not a substitute for your own product instructions.